Conmed Corporation revenue by segment CNMD

Conmed Corporation splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was General Surgery at $186.7 million, 56% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Sep 30, 2026
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Revenue
1,369
336
343
373
338
342
321
346
317
General Surgery
763
-3.6%
share 55.7%
187
-6.5%
share 55.6%
191
-5.2%
share 55.7%
216
+4.3%
share 57.8%
200
+7.3%
share 59.1%
202
share 58.9%
183
share 57.0%
207
share 59.8%
186
share 58.8%
Orthopedic Surgery
606
+9.0%
share 44.3%
149
+7.7%
share 44.4%
152
+8.2%
share 44.3%
157
+13.2%
share 42.2%
138
+5.9%
share 40.9%
141
share 41.1%
138
share 43.0%
139
share 40.2%
131
share 41.2%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
CNMD (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Largo, FL
SEC filer status
Large accelerated filer
SEC CIK
816956

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.